NCT02500316 - Long Term Follow up Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

November 30, 2023

Study Completion Date

November 30, 2023

Conditions

Growth Hormone Deficiency (GHD)

Interventions

DRUG

MOD-4023

Once weekly injection of long acting r-hGH (MOD-4023) provided as a solution for injection containing 20 or 50 mg/mL MOD-4023 in a single patient use, multi-dose, disposable pre-filled pen (PEN).

Trial Locations (13)

32207

Nemours Children's Clinic, Jacksonville

Unknown

2DKB, Minsk

"Children's Hospital P. A. Kyriakou", Athens

Buda Children's Hospital, Budapest

Endocrinology Scientific Centre, Institute of Child Endocrinology, Moscow

Russian Medical Academy of Postgraduate Education, Moscow

SPGPMA, Saint Petersburg

SamGMU, Samara

SBEIHPE, Ufa

Donetsk Regional Children Clinical Hospital, Donetsk

Institute of Endocrinology, Kiev

Ukrainian Scientific Center of Endocrine Surgery Moh of Ukraine, Kiev

Odessa Regional Children'S Clinical Hospital, Odesa

All Listed Sponsors

lead

OPKO Health, Inc.

INDUSTRY